Genticel s’introduit en Bourse sur Euronext à Paris et à Bruxelles


Brussels, Paris 4 April 2014 – EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs[1],today congratulated Genticel, a French biotechnology company and specialist in the development of therapeutic vaccines whose objective is to eliminate the human papillomavirus (HPV) responsible for cervical cancer, on its successful admission to trading on Euronext’s compartment C in Paris and in Brussels.

Based in Paris and Toulouse, Genticel develops therapeutic vaccines against cervical cancer. Its vaccine candidates are aimed at eliminating, at an early stage, cells carrying the human papillomavirus (HPV) responsible for cervical cancer, one of the most common cancers of women worldwide. ProCervix, a “first-in-class” therapeutic vaccine candidate currently in Phase II clinical trials, is designed to eliminate cells infected by type 16 and/or type 18 HPV virus located at the cervix of the uterus before the development of high-grade or cancerous lesions, thus addressing a serious public health problem. Genticel is also developing a second therapeutic vaccine candidate called Multivalent HPV that targets six strains of cancerous HPV.   

Genticel (ticker symbol: GTCL) was listed through the admission to trading of existing shares making up the company’s equity and the sale of 4,367,088 newly issued shares, resulting in a capital increase of €34.5 million.

The admission and issue price of Genticel shares was set at €7.90 per share, leading to a market capitalisation of approximately €119.4 million.

“We congratulate Genticel on its dual listing in Paris and Brussels. This IPO will help the company raise its liquidity and visibility with investor communities, both domestic and international,” said Eric Forest, Chairman and CEO of EnterNext. “EnterNext will be advising and assisting Genticel at each stage in its growth and participation in trading, in particular to help it make best use of the range of financing solutions available to it on our markets.”   

Benedikt Timmerman, Genticel founder and CEO, said: “We are delighted with investors’ response to our company and with our successful IPO. We would like to extend warm thanks to all the investors that joined us on this occasion, as well as our historic  shareholders who renewed their confidence in our company as we reached this important milestone in Genticel’s growth. We are also very pleased with the interest shown by individual investors, particularly in Belgium, and took extra measures to better meet their demand for shares. We now have the financial resources we need to develop our portfolio of candidate therapeutic vaccines, which are designed to give therapeutic options to women carrying the human papillomavirus and thereby reduce the number of cases of cervix carcinoma. In particular, Genticel will continue developing ProCervix, our lead candidate, which has blockbuster potential, with a view to forging a value-creating industrial partnership within the next few years.”

[1]Small and medium-sized entreprises

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end June 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter ( and LinkedIn (

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at

© 2023, Euronext N.V. - All rights reserved.